Teva Pharmaceuticals USA has agreed to delay sales of generic versions of two Gilead Sciences HIV drugs until June 1, 2013, pending a favorable court decision in the long-running patent suit.
The case, Gilead Sciences, Inc. v. Teva Pharmaceuticals USA, et al., is set for trial Feb. 20, 2013, in the U.S. District Court for the Southern District of New York. Teva may launch copycats of Truvada (emtricitabine/tenofovir disoproxil fumarate) and Viread (tenofovir disoproxil fumarate) June 1 if there is no ruling holding that the patents-in-suit are invalid or unenforceable, according to an agreement between the two drugmakers that was filed Tuesday.
Gilead sued Teva in 2008 for infringing on two patents covering the HIV treatment Truvada. Teva maintains the drug’s ’245 and ’396 patents, owned by Emory University and licensed solely to Gilead, are invalid due to obviousness-type double patenting.
There’s money to be made in the global generic drug market, but it helps to know which countries are up, which are down and which are coming into their own? Which companies are working together, who’s suing whom and how could developments inside top industry players affect expansion for makers of generics and biologics?
The answers you need today to identify the best — and safest — business prospects for the years ahead can be found in World Generic Market Report 2012.
With original research, country-by-country comparisons and five-year market forecasts, this two-volume report gives you the power to identify — and seize — the best expansion opportunities around the globe. Hundreds of millions can be made, as evident with Revatio. Don’t delay. Order your copy of this must-have report today!
Thread abonnieren
